PGLYRP4

Across TCGA pan-cancer cohorts, PGLYRP4 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PGLYRP4’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where PGLYRP4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PGLYRP4 is over-expressed in tumor.

LUSC, LUAD, and HNSC are the cancer types where PGLYRP4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PGLYRP4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	Female	II,III,IV	+2.544	<.001	8	view →
LUAD	Female	II,III,IV	+1.616	<.001	8	view →
HNSC	Female	All	+0.982	.007	5	view →
BLCA	Male	III,IV	+2.812	.018	4	view →
BRCA	Female	All	+0.264	.001	4	view →
COAD	All	All	+0.205	.002	4	view →
KIRC	Male	All	+0.021	.016	3	view →
CHOL	All	All	+0.345	.012	1	view →
KIRP	Female	All	+0.075	.034	1	view →
THCA	All	All	+0.027	.034	1	view →
LIHC	Female	All	+0.016	.034	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PGLYRP4–LUSC

Open the LUSC breakdown →